Overdiagnosis and overtreatment of indolent prostate cancer (PCa) in aging men pose significant risks in the management of PCa (1) due to the prevalence of the disease, the usual accessibility of the prostate-specific antigen (PSA) test, and the long-term effects of radical treatments. This evidence concerns the gene KLK3 and posterior cortical atrophy.